Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.57 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.57 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.57 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | OGG1 | O15527 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205675 | 0.98 | GSK3B (0.64) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| Bromide SCHEMBL17185185 | 0.95 | GSK3B (0.61) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL13738814 | 0.88 | GSK3B (0.42) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL690938 | 0.81 | SMN1; SMN2 (0.48) | GSK3BHAO1HPGDRAB9AALDH1A1 | |
| SCHEMBL20799581 | 0.80 | GSK3B (0.59) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL6455838 | 0.79 | NPC1 (0.58) | CA1CA2NPC1HPGDRAB9A | |
| Hydrochloric Acid SCHEMBL9064086 | 0.79 | GSK3B (0.95) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL241664 | 0.78 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL1305020 | 0.78 | GSK3B (0.70) | GSK3BHDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL883159 | 0.78 | SMN1; SMN2 (0.50) | GSK3BHAO1HPGDRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0877298-B1 | Coated xerographic photographic paper | XEROX CORP (US) | 2001-08-29 | — | — | EP | claimed |
| US-5908723-A | Recording sheets | XEROX CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| US-5846637-A | Coated xerographic photographic paper | XEROX CORPORATION (US) | 1998-12-08 | — | — | US | claimed |
| EP-0877298-A2 | Coated xerographic photographic paper | Xerox Corporation (US) | 1998-11-11 | — | — | EP | claimed |
| CN-115819366-B | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2024-05-24 | — | — | CN | disclosed |
| CN-117751113-A | Aromatic acetylene derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114702501-B | Imidazole peptide deformylase inhibitor with anti-tumor effect | 中山大学 | 2023-10-17 | — | — | CN | disclosed |
| CN-115819366-A | Preparation method of 2-aroyl substituted oxazole compound and compound prepared by same | 重庆医科大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-114874143-A | Regulator containing pyrazole derivatives, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114702501-A | Imidazole peptide deformylase inhibitor with anti-tumor effect | 中山大学 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022115384-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| CN-106588890-B | Antiviral compounds | 吉利德制药有限责任公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-0379145-B1 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID CO (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5041567-A | Human and veterianary medicine; veneral diseases respiratory diseases, bovine mastitis | BEECHAM GROUP PLC (GB) | 1991-08-20 | — | — | US | disclosed |
| US-4968702-A | ANTIARTHRITIC, INHIBITORS OF PROGRESSIVE JOINT DETERIORATION, IMMUNOSUPPRESSANT | AMERICAN CYANAMID COMPANY (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0379145-A2 | Substituted quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-25 | — | — | EP | disclosed |
| US-4812470-A | Antibacterial monic acid derivatives | BEECHAM GROUP P.L.C. (GB) | 1989-03-14 | — | — | US | disclosed |
| EP-0087953-B1 | ANTIBACTERIAL 1-NORMON-2-YL-HETEROCYCLIC COMPOUNDS | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
| EP-0087953-A2 | Antibacterial 1-normon-2-yl-heterocyclic compounds | BEECHAM GROUP PLC (GB) | 1983-09-07 | — | — | EP | disclosed |
| US-4171307-A | 5-(4-Bromophenyl)oxazole | MORTON-NORWICH PRODUCTS, INC. (US) | 1979-10-16 | — | — | US | disclosed |